{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:08:33Z","timestamp":1793196513275,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,11,10]],"date-time":"2018-11-10T00:00:00Z","timestamp":1541808000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s11938-018-0209-8","type":"journal-article","created":{"date-parts":[[2018,11,10]],"date-time":"2018-11-10T01:07:32Z","timestamp":1541812052000},"page":"605-615","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Helicobacter pylori Infection: New Facts in Clinical Management"],"prefix":"10.1007","volume":"16","author":[{"given":"Peter","family":"Malfertheiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marino","family":"Venerito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,10]]},"reference":[{"issue":"2","key":"209_CR1","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1053\/j.gastro.2017.04.022","volume":"153","author":"JKY Hooi","year":"2017","unstructured":"Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420\u20139. \n                      https:\/\/doi.org\/10.1053\/j.gastro.2017.04.022\n                      \n                    .","journal-title":"Gastroenterology"},{"issue":"07","key":"209_CR2","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1055\/s-0043-106311","volume":"55","author":"Caspar Franck","year":"2017","unstructured":"Franck C, Hoffmann A, Link A, et al. Prevalence of Helicobacter pylori infection among blood donors in Saxony-Anhalt, Germany - a region at intermediate risk for gastric Cancer. Z Gastroenterol. 2017;55 (7) ,653-656.","journal-title":"Zeitschrift f\u00fcr Gastroenterologie"},{"issue":"3","key":"209_CR3","doi-asserted-by":"publisher","first-page":"e12483","DOI":"10.1111\/hel.12483","volume":"23","author":"K Venneman","year":"2018","unstructured":"Venneman K, Huybrechts I, Gunter MJ, Vandendaele L, Herrero R, Van Herck K. The epidemiology of Helicobacter pylori infection in Europe and the impact of lifestyle on its natural evolution toward stomach cancer after infection: a systematic review. Helicobacter. 2018;23(3):e12483. \n                      https:\/\/doi.org\/10.1111\/hel.12483\n                      \n                    .","journal-title":"Helicobacter"},{"issue":"1","key":"209_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-15490-7","volume":"7","author":"C Wang","year":"2017","unstructured":"Wang C, Nishiyama T, Kikuchi S, et al. Changing trends in the prevalence of H. pylori infection in Japan (1908\u20132003): a systematic review and meta-regression analysis of 170,752 individuals. Sci Rep. 2017;7(1):1\u201312. \n                      https:\/\/doi.org\/10.1038\/s41598-017-15490-7\n                      \n                    .","journal-title":"Sci Rep"},{"issue":"2","key":"209_CR5","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/ajg.2016.563","volume":"112","author":"WD Chey","year":"2017","unstructured":"\u2022 Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212\u201339. \n                      https:\/\/doi.org\/10.1038\/ajg.2016.563\n                      \n                     Provides a comprehensive insight in clinical developments of H. pylori infection with recommendations for management with focus on practice in US.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"209_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/j.gastro.2016.04.006","volume":"151","author":"CA Fallone","year":"2016","unstructured":"\u2022 Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151(1):51\u201369.e14. \n                      https:\/\/doi.org\/10.1053\/j.gastro.2016.04.006\n                      \n                     Thourough assessment of available and recommended eradication therapies.","journal-title":"Gastroenterology"},{"issue":"1","key":"209_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","volume":"66","author":"P Malfertheiner","year":"2016","unstructured":"\u2022 Malfertheiner P, Megraud F, O\u2019Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V\/Florence consensus report. Gut. 2016;66(1):6\u201330. \n                      https:\/\/doi.org\/10.1136\/gutjnl-2016-312288\n                      \n                     Update on all clinical aspects related to H. pylori infection includung future directions concerning screen and treat strategies, update on treatment recommendations and adressing the new focus on gastric microbiota beyond H. pylori.","journal-title":"Gut"},{"issue":"1","key":"209_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/jgh.13911","volume":"33","author":"V Mahachai","year":"2018","unstructured":"\u2022 Mahachai V, Vilaichone R, Pittayanon R, et al. Helicobacter pylori management in ASEAN: The Bangkok consensus report. J Gastroenterol Hepatol. 2018;33(1):37\u201356. \n                      https:\/\/doi.org\/10.1111\/jgh.13911\n                      \n                     Focus on clinical aspects of H. pylori infection in Asia and recommendations for clinical managment.","journal-title":"J Gastroenterol Hepatol"},{"key":"209_CR9","unstructured":"Ra\u017euka-Ebela D, Bianca Giupponi FF. The year in Helicobacter. Helicobacter. 2018."},{"issue":"1","key":"209_CR10","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/bjd.14930","volume":"176","author":"A Egeberg","year":"2017","unstructured":"Egeberg A, Weinstock LB, Thyssen EP, Gislason GH, Thyssen JP. Rosacea and gastrointestinal disorders: a population-based cohort study. Br J Dermatol. 2017;176(1):100\u20136. \n                      https:\/\/doi.org\/10.1111\/bjd.14930\n                      \n                    .","journal-title":"Br J Dermatol"},{"issue":"70","key":"209_CR11","doi-asserted-by":"publisher","first-page":"115691","DOI":"10.18632\/oncotarget.22929","volume":"8","author":"Y Hou","year":"2017","unstructured":"Hou Y, Sun W, Zhang C, et al. Meta-analysis of the correlation between Helicobacter pylori infection and autoimmune thyroid diseases. Oncotarget. 2017;8(70):115691\u2013700. \n                      https:\/\/doi.org\/10.18632\/oncotarget.22929\n                      \n                    .","journal-title":"Oncotarget"},{"issue":"7","key":"209_CR12","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1111\/apt.13560","volume":"43","author":"U. von Arnim","year":"2016","unstructured":"Von Arnim U, Wex T, Link A, et al. Helicobacter pylori infection is associated with a reduced risk of developing eosinophilic oesophagitis. Aliment Pharmacol Ther. 2016;43(7). \n                      https:\/\/doi.org\/10.1111\/apt.13560\n                      \n                    .","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"7","key":"209_CR13","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/s41395-018-0035-6","volume":"113","author":"J Molina-Infante","year":"2018","unstructured":"Molina-Infante J, Gutierrez-Junquera C, Savarino E, et al. Helicobacter pylori infection does not protect against eosinophilic esophagitis: results from a large multicenter case-control study. Am J Gastroenterol. 2018;113(7):972\u20139. \n                      https:\/\/doi.org\/10.1038\/s41395-018-0035-6\n                      \n                    .","journal-title":"Am J Gastroenterol"},{"key":"209_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fcimb.2012.00010","volume":"2","author":"IC Arnold","year":"2012","unstructured":"Arnold IC, Hitzler I, M\u00fcller A. The immunomodulatory properties of Helicobacter pylori confer protection against allergic and chronic inflammatory disorders. Front Cell Infect Microbiol. 2012;2:10. \n                      https:\/\/doi.org\/10.3389\/fcimb.2012.00010\n                      \n                    .","journal-title":"Front Cell Infect Microbiol"},{"issue":"46","key":"209_CR15","doi-asserted-by":"publisher","first-page":"17635","DOI":"10.3748\/wjg.v20.i46.17635","volume":"20","author":"E Lionetti","year":"2014","unstructured":"Lionetti E, Leonardi S, Lanzafame A, Garozzo MT, Filippelli M, Tomarchio S, et al. Helicobacter pylori infection and atopic diseases: is there a relationship? A systematic review and meta-analysis. World J Gastroenterol. 2014;20(46):17635\u201347. \n                      https:\/\/doi.org\/10.3748\/wjg.v20.i46.17635\n                      \n                    .","journal-title":"World J Gastroenterol"},{"issue":"8","key":"209_CR16","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/apt.13572","volume":"43","author":"WJ Hollander den","year":"2016","unstructured":"den Hollander WJ, Sonnenschein-van der Voort AMM, Holster IL, et al. Helicobacter pylori in children with asthmatic conditions at school age, and their mothers. Aliment Pharmacol Ther. 2016;43(8):933\u201343. \n                      https:\/\/doi.org\/10.1111\/apt.13572\n                      \n                    .","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"209_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/ecco-jcc\/jjx135","volume":"12","author":"S Aniwan","year":"2018","unstructured":"Aniwan S, Tremaine WJ, Raffals LE, Kane SV, Loftus EV. Antibiotic use and new-onset inflammatory bowel disease in Olmsted county, Minnesota: a population-based case-control study. J Crohn\u2019s Colitis. 2018;12(2):137\u201344. \n                      https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx135\n                      \n                    .","journal-title":"J Crohn\u2019s Colitis"},{"key":"209_CR18","doi-asserted-by":"publisher","unstructured":"Rosania R, Arnim UV, Link A, et al. Helicobacter pylori eradication therapy is not associated with the onset of inflammatory bowel diseases. A case-control study. J Gastrointest Liver Dis. 2018;27(2). \n                      https:\/\/doi.org\/10.15403\/jgld.2014.1121.272.hpy\n                      \n                    .","DOI":"10.15403\/jgld.2014.1121.272.hpy"},{"key":"209_CR19","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1136\/gutjnl-2018-316276","volume":"67","author":"JJ Sung","year":"2018","unstructured":"Sung JJ, Chiu PC, Chan FKL, et al. Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018. Gut. 2018;67:1757\u201368. \n                      https:\/\/doi.org\/10.1136\/gutjnl-2018-316276\n                      \n                    .","journal-title":"Gut"},{"issue":"3","key":"209_CR20","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1053\/j.gastro.2012.12.038","volume":"144","author":"FKL Chan","year":"2013","unstructured":"Chan FKL, Ching JYL, Suen BY, Tse YK, Wu JCY, Sung JJY. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology. 2013;144(3):528\u201335. \n                      https:\/\/doi.org\/10.1053\/j.gastro.2012.12.038\n                      \n                    .","journal-title":"Gastroenterology"},{"issue":"5","key":"209_CR21","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/ajg.2015.98","volume":"110","author":"C Sostres","year":"2015","unstructured":"Sostres C, Carrera-Lasfuentes P, Benito R, et al. Peptic ulcer bleeding risk. The role of Helicobacter pylori infection in NSAID\/low-dose aspirin users. Am J Gastroenterol. 2015;110(5):684\u20139. \n                      https:\/\/doi.org\/10.1038\/ajg.2015.98\n                      \n                    .","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"209_CR22","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1111\/apt.14652","volume":"47","author":"M. Venerito","year":"2018","unstructured":"Venerito M, Schneider C, Costanzo R, Breja R, R\u00f6hl FW, Malfertheiner P. Contribution of Helicobacter pylori infection to the risk of peptic ulcer bleeding in patients on nonsteroidal anti-inflammatory drugs, antiplatelet agents, anticoagulants, corticosteroids and selective serotonin reuptake inhibitors. Aliment Pharmacol Ther. 2018;(December 2017). \n                      https:\/\/doi.org\/10.1111\/apt.14652","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"4","key":"209_CR23","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S2468-1253(18)30037-2","volume":"3","author":"B Scally","year":"2018","unstructured":"Scally B, Emberson JR, Spata E, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol. 2018;3(4):231\u201341. \n                      https:\/\/doi.org\/10.1016\/S2468-1253(18)30037-2\n                      \n                    .","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"209_CR24","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1053\/j.gastro.2017.07.049","volume":"154","author":"CP Gyawali","year":"2018","unstructured":"Gyawali CP, Fass R. Management of gastroesophageal reflux disease. Gastroenterology. 2018;154(2):302\u201318. \n                      https:\/\/doi.org\/10.1053\/j.gastro.2017.07.049\n                      \n                    .","journal-title":"Gastroenterology"},{"issue":"12","key":"209_CR25","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nrgastro.2017.117","volume":"14","author":"P Malfertheiner","year":"2017","unstructured":"Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017;14(12):697\u2013710. \n                      https:\/\/doi.org\/10.1038\/nrgastro.2017.117\n                      \n                    .","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"209_CR26","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1038\/sj.bjc.6605024","volume":"100","author":"AH Poulsen","year":"2009","unstructured":"Poulsen AH, Christensen S, McLaughlin JK, et al. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. Br J Cancer. 2009;100(9):1503\u20137. \n                      https:\/\/doi.org\/10.1038\/sj.bjc.6605024\n                      \n                    .","journal-title":"Br J Cancer"},{"issue":"12","key":"209_CR27","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/j.cgh.2016.05.018","volume":"14","author":"A Tran-Duy","year":"2016","unstructured":"Tran-Duy A, Spaetgens B, Hoes AW, de Wit NJ, Stehouwer CDA. Use of proton pump inhibitors and risks of fundic gland polyps and gastric cancer: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(12):1706\u20131719.e5. \n                      https:\/\/doi.org\/10.1016\/j.cgh.2016.05.018\n                      \n                    .","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"209_CR28","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1136\/gutjnl-2017-314605","volume":"67","author":"Ka Shing Cheung","year":"2017","unstructured":"Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori : a population-based study. Gut. 2017;gutjnl-2017-314605. \n                      https:\/\/doi.org\/10.1136\/gutjnl-2017-314605","journal-title":"Gut"},{"issue":"2","key":"209_CR29","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1136\/gutjnl-2017-314205","volume":"67","author":"RM Ferreira","year":"2018","unstructured":"Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I, Costa JL, Carneiro F, Machado JC, et al. Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut. 2018;67(2):226\u201336. \n                      https:\/\/doi.org\/10.1136\/gutjnl-2017-314205\n                      \n                    .","journal-title":"Gut"},{"issue":"9","key":"209_CR30","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","volume":"64","author":"K Sugano","year":"2015","unstructured":"Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353\u201367. \n                      https:\/\/doi.org\/10.1136\/gutjnl-2015-309252\n                      \n                    .","journal-title":"Gut"},{"issue":"5","key":"209_CR31","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1053\/j.gastro.2016.01.028","volume":"150","author":"Y-C Lee","year":"2016","unstructured":"Lee Y-C, Chiang T-H, Chou C-K, et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology. 2016;150(5):1113\u20131124.e5. \n                      https:\/\/doi.org\/10.1053\/j.gastro.2016.01.028\n                      \n                    .","journal-title":"Gastroenterology"},{"issue":"8","key":"209_CR32","doi-asserted-by":"publisher","first-page":"e0183321","DOI":"10.1371\/journal.pone.0183321","volume":"12","author":"T Seta","year":"2017","unstructured":"Seta T, Takahashi Y, Noguchi Y, et al. Effectiveness of Helicobacter pylori eradication in the prevention of primary gastric cancer in healthy asymptomatic people: A systematic review and meta-analysis comparing risk ratio with risk difference. Katoh M, ed. PLoS One. 2017;12(8):e0183321. \n                      https:\/\/doi.org\/10.1371\/journal.pone.0183321\n                      \n                    .","journal-title":"PLoS One"},{"issue":"12","key":"209_CR33","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1136\/gutjnl-2017-315363","volume":"67","author":"Eva Doorakkers","year":"2018","unstructured":"Doorakkers E, Lagergren J, Engstrand L, Brusselaers N. Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a Western population. Gut. 2018;gutjnl-2017-315363. \n                      https:\/\/doi.org\/10.1136\/gutjnl-2017-315363","journal-title":"Gut"},{"issue":"12","key":"209_CR34","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1056\/NEJMoa1708423","volume":"378","author":"IJ Choi","year":"2018","unstructured":"\u2022\u2022 Choi IJ, Kook M-C, Kim Y-I, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med. 2018;378(12):1085\u201395. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1708423\n                      \n                     First randomized prospective controlled trial providing evidence that H. pylori eradication prevents the development of metachronous gastric cancer following the endoscopic removal of early gastic cancer in a significant proportion of patients; suggests that H. pylori eradication will always remain beneficial although less effective in advanced stage of chronic atrophic gastritis.","journal-title":"N Engl J Med"},{"issue":"4","key":"209_CR35","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1586\/17474124.2016.1126507","volume":"10","author":"Marino Venerito","year":"2016","unstructured":"Venerito M, Goni E, Malfertheiner P. Helicobacter pylori screening: options and challenges. Expert Rev Gastroenterol Hepatol. 2016;10(4). \n                      https:\/\/doi.org\/10.1586\/17474124.2016.1126507","journal-title":"Expert Review of Gastroenterology & Hepatology"},{"issue":"12","key":"209_CR36","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1056\/NEJMe1800147","volume":"378","author":"P Malfertheiner","year":"2018","unstructured":"Malfertheiner P. Helicobacter pylori treatment for gastric cancer prevention. N Engl J Med. 2018;378(12):1154\u20136. \n                      https:\/\/doi.org\/10.1056\/NEJMe1800147\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"7","key":"209_CR37","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/apt.14248","volume":"46","author":"RM Zagari","year":"2017","unstructured":"Zagari RM, Rabitti S, Greenwood DC, Eusebi LH, Vestito A, Bazzoli F. Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis. Aliment Pharmacol Ther. 2017;46(7):657\u201367. \n                      https:\/\/doi.org\/10.1111\/apt.14248\n                      \n                    .","journal-title":"Aliment Pharmacol Ther"},{"issue":"11\u201312","key":"209_CR38","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1111\/apt.14340","volume":"46","author":"P Malfertheiner","year":"2017","unstructured":"Malfertheiner P. Editorial: the non-invasive diagnosis of atrophic gastritis. Aliment Pharmacol Ther. 2017;46(11\u201312):1112\u20133. \n                      https:\/\/doi.org\/10.1111\/apt.14340\n                      \n                    .","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"209_CR39","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1111\/cas.12829","volume":"106","author":"C Hamashima","year":"2015","unstructured":"Hamashima C, Shabana M, Okada K, Okamoto M, Osaki Y. Mortality reduction from gastric cancer by endoscopic and radiographic screening. Cancer Sci. 2015;106(12):1744\u20139. \n                      https:\/\/doi.org\/10.1111\/cas.12829\n                      \n                    .","journal-title":"Cancer Sci"},{"issue":"6","key":"209_CR40","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1053\/j.gastro.2017.01.029","volume":"152","author":"JK Jun","year":"2017","unstructured":"Jun JK, Choi KS, Lee H-Y, et al. Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality. Gastroenterology. 2017;152(6):1319\u20131328.e7. \n                      https:\/\/doi.org\/10.1053\/j.gastro.2017.01.029\n                      \n                    .","journal-title":"Gastroenterology"},{"issue":"4","key":"209_CR41","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/apt.14471","volume":"47","author":"M Song","year":"2018","unstructured":"Song M, Camargo MC, Weinstein SJ, Murphy G, Freedman ND, Koshiol J, et al. Serum pepsinogen 1 and anti-Helicobacter pylori IgG antibodies as predictors of gastric cancer risk in Finnish males. Aliment Pharmacol Ther. 2018;47(4):494\u2013503. \n                      https:\/\/doi.org\/10.1111\/apt.14471\n                      \n                    .","journal-title":"Aliment Pharmacol Ther"},{"key":"209_CR42","doi-asserted-by":"crossref","unstructured":"Venerito M, Vasapolli R, Theodoros Rokkas PM. Gastric cancer: epidemiology, prevention and therapy. Helicobacter. 2018;suppl.1 e12518.","DOI":"10.1111\/hel.12518"},{"issue":"10","key":"209_CR43","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/apt.13588","volume":"43","author":"T Kagami","year":"2016","unstructured":"Kagami T, Sahara S, Ichikawa H, Uotani T, Yamade M, Sugimoto M, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther. 2016;43(10):1048\u201359. \n                      https:\/\/doi.org\/10.1111\/apt.13588\n                      \n                    .","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"209_CR44","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12495","volume":"23","author":"M Li","year":"2018","unstructured":"Li M, Oshima T, Horikawa T, Tozawa K, Tomita T, Fukui H, et al. Systematic review with meta-analysis: vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori. Helicobacter. 2018;23(4):e12495. \n                      https:\/\/doi.org\/10.1111\/hel.12495\n                      \n                    .","journal-title":"Helicobacter"},{"key":"209_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14787210.2018.1511427","volume":"16","author":"DY Graham","year":"2018","unstructured":"Graham DY, Dore MP, Lu H. Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies. Expert Rev Anti-Infect Ther. 2018;16:1\u20139. \n                      https:\/\/doi.org\/10.1080\/14787210.2018.1511427\n                      \n                    .","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"9699","key":"209_CR46","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/S0140-6736(09)60938-7","volume":"374","author":"P Malfertheiner","year":"2009","unstructured":"Malfertheiner P, Chan FK, EL McColl K. Peptic ulcer disease. Lancet. 2009;374(9699):1449\u201361. \n                      https:\/\/doi.org\/10.1016\/S0140-6736(09)60938-7\n                      \n                    .","journal-title":"Lancet"},{"issue":"1","key":"209_CR47","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1159\/000350719","volume":"88","author":"Marino Venerito","year":"2013","unstructured":"Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion. 2013;88(1). \n                      https:\/\/doi.org\/10.1159\/000350719","journal-title":"Digestion"},{"issue":"3","key":"209_CR48","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318\u201327. \n                      https:\/\/doi.org\/10.1016\/S1473-3099(17)30753-3\n                      \n                    .","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"209_CR49","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1111\/apt.14597","volume":"47","author":"L Gatta","year":"2018","unstructured":"Gatta L, Scarpignato C, Fiorini G, Belsey J, Saracino IM, Ricci C, et al. Impact of primary antibiotic resistance on the effectiveness of sequential therapy for Helicobacter pylori infection: lessons from a 5-year study on a large number of strains. Aliment Pharmacol Ther. 2018;47(9):1261\u20139. \n                      https:\/\/doi.org\/10.1111\/apt.14597\n                      \n                    .","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"209_CR50","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/apt.13497","volume":"43","author":"I Thung","year":"2016","unstructured":"Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43(4):514\u201333. \n                      https:\/\/doi.org\/10.1111\/apt.13497\n                      \n                    .","journal-title":"Aliment Pharmacol Ther"},{"issue":"14","key":"209_CR51","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.3748\/wjg.v23.i14.2453","volume":"23","author":"E Ierardi","year":"2017","unstructured":"Ierardi E, Giorgio F, Iannone A, Losurdo G, Principi M, Barone M, et al. Noninvasive molecular analysis of Helicobacter pylori : is it time for tailored first-line therapy? World J Gastroenterol. 2017;23(14):2453\u20138. \n                      https:\/\/doi.org\/10.3748\/wjg.v23.i14.2453\n                      \n                    .","journal-title":"World J Gastroenterol"},{"issue":"6","key":"209_CR52","doi-asserted-by":"publisher","first-page":"e12447","DOI":"10.1111\/hel.12447","volume":"22","author":"N Pastukh","year":"2017","unstructured":"Pastukh N, Binyamin D, On A, Paritsky M, Peretz A. GenoType\u00ae HelicoDR test in comparison with histology and culture for Helicobacter pylori detection and identification of resistance mutations to clarithromycin and fluoroquinolones. Helicobacter. 2017;22(6):e12447.\n                      https:\/\/doi.org\/10.1111\/hel.12447\n                      \n                    .","journal-title":"Helicobacter"},{"key":"209_CR53","doi-asserted-by":"publisher","first-page":"e12515","DOI":"10.1111\/hel.12515","volume":"23","author":"Sabine Skrebinska","year":"2018","unstructured":"Skrebinska S, Megraud F, Bessede F. Diagnosis of H.pylori. Helicobacter. 2018;23 suppl 1. \n                      https:\/\/doi.org\/10.1111\/hel.12515","journal-title":"Helicobacter"},{"issue":"3","key":"209_CR54","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3892\/etm.2015.2174","volume":"9","author":"Z Lv","year":"2015","unstructured":"Lv Z, Wang B, Zhou X, et al. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: a meta-analysis. Exp Ther Med. 2015;9(3):707\u201316. \n                      https:\/\/doi.org\/10.3892\/etm.2015.2174\n                      \n                    .","journal-title":"Exp Ther Med"},{"issue":"11","key":"209_CR55","doi-asserted-by":"publisher","first-page":"e111030","DOI":"10.1371\/journal.pone.0111030","volume":"9","author":"Y Dang","year":"2014","unstructured":"Dang Y, Reinhardt JD, Zhou X, Zhang G. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. PLoS One. 2014;9(11):e111030. \n                      https:\/\/doi.org\/10.1371\/journal.pone.0111030\n                      \n                    .","journal-title":"PLoS One"},{"issue":"4","key":"209_CR56","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1177\/2050640615617358","volume":"4","author":"LV McFarland","year":"2016","unstructured":"McFarland LV, Huang Y, Wang L, Malfertheiner P. Systematic review and meta-analysis: multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events. United Eur Gastroenterol J. 2016;4(4):546\u201361. \n                      https:\/\/doi.org\/10.1177\/2050640615617358\n                      \n                    .","journal-title":"United Eur Gastroenterol J"},{"issue":"11","key":"209_CR57","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1111\/apt.13163","volume":"41","author":"H Szajewska","year":"2015","unstructured":"Szajewska H, Shamir R, Chmielewska A, et al. Systematic review with meta-analysis: early infant feeding and coeliac disease\u2013update 2015. Aliment Pharmacol Ther. 2015;41(11):1038\u201354. \n                      https:\/\/doi.org\/10.1111\/apt.13163\n                      \n                    .","journal-title":"Aliment Pharmacol Ther"},{"key":"209_CR58","doi-asserted-by":"publisher","first-page":"e12529","DOI":"10.1111\/hel.12529","volume":"23","author":"AG McNicholl","year":"2018","unstructured":"McNicholl AG, Molina-Infante J, Lucendo AJ, et al. Probiotic supplementation with Lactobacillus plantarum and Pediococcus acidilactici for Helicobacter pylori therapy: a randomized, double-blind, placebo-controlled trial. Helicobacter. 2018;23:e12529. \n                      https:\/\/doi.org\/10.1111\/hel.12529\n                      \n                    .","journal-title":"Helicobacter"}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11938-018-0209-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-018-0209-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-018-0209-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T19:19:30Z","timestamp":1573327170000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11938-018-0209-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,10]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["209"],"URL":"https:\/\/doi.org\/10.1007\/s11938-018-0209-8","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"value":"1092-8472","type":"print"},{"value":"1534-309X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,10]]},"assertion":[{"value":"10 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Peter Malfertheiner is involved in speakers bureau\/or consulting: Biocodex, Biohit, Danone, Mayoly- Spindler. Marino Venerito declares that he has no conflict of interest. Christian Schulz declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}